Skip to content

Clinical study of the prognostic relevance of SII, SIRI and their combination in patients with heart failure

Clinical study of the prognostic relevance of SII, SIRI and their combination in patients with heart failure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096717
Enrollment
Unknown
Registered
2025-02-05
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Mace group/No MACE group:None

Sponsors

Northern Jiangsu People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: According to the 2018 Chinese Heart Failure Guidelines, patients discharged with a diagnosis of heart failure and with a complete blood count within 24 h of admission to the hospital

Exclusion criteria

Exclusion criteria: Combined severe hepatic and renal insufficiency (ALT more than triple and above, chronic kidney disease stage 4 or 5, or blood creatinine >265 µmol/L); combined infections; patients with history of malignancy and radiotherapy, hyperthyroidism, connective tissue disease, and blood disorders affecting CBC in the last one year; patients with recent need for transfusion and invasive mechanical ventilation; and patients who did not undergo CBC in the last 24h.

Design outcomes

Primary

MeasureTime frame
Systemic Inflammatory Index(SII);Systemic Inflammatory Response Index (SIRI);

Countries

China

Contacts

Public ContactZhang Jing

Northern Jiangsu People's Hospital

zhangjingyjs@163.com+86 159 5273 9006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026